Tovecimig meets primary endpoint in Phase 2/3 BTC trial: 17.1% ORR vs 5.3% (p=0.031)

Compass Therapeutics, Inc.

ORR 17.1% for tovecimig+paclitaxel (19/111) vs 5.3% for paclitaxel alone (3/57), p=0.031, statistically significant.
One complete response in combo arm; progressive disease rate 16.2% vs 42.1%.
Secondary endpoints (PFS, OS, DoR) not yet mature; expected Q4 2025 after 80% event threshold.
Safety consistent with prior studies; DMC recommended continuation after four reviews.
BTC affects ~23,000 US patients annually; ~85% lack approved second-line targeted therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.